Targets to Therapeutics in Pancreatic Cancer

胰腺癌的治疗目标

• 批准号: 7666112
• 负责人: DANIEL D VON HOFF
• 金额: $ 304.63万
• 依托单位: TRANSLATIONAL GENOMICS RESEARCH INST
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7666112
• 关键词: Targets; Therapeutics; Pancreatic; Cancer

DESCRIPTION (provided by applicant): Pancreatic cancer is now the fourth leading cause of death from cancer in women and men in the United States. New, innovative approaches to the prevention and treatment of pancreatic cancer are sorely needed. This Program Project Grant (P01) application in pancreatic cancer takes up that challenging need, building on a strong foundation of interest and expertise in pancreatic cancer and in drug development at the Arizona Cancer Center (AZCC) at the University of Arizona. The central theme and goal of this P01 is to speed delivery into the clinic of new therapeutic agents against new targets in pancreatic cancer. The goal of this P01 is that in each year of this P01, we will deliver a new agent into clinical trials in patients with pancreatic cancer, which hits a target discovered and validated in one of the projects of this P01. This P01 application represents a revised application that we feel is an improved, more focused effort against the disease. Responses to each of the critiques are presented in the beginning of each section of the application. Two years ago, the AZCC formed the Sydney Salmon Pancreatic Cancer Team (named after the founding director of the AZCC who passed away from the disease). The team has built an infrastructure of investigators (established and new, in basic, translational, and clinical research), developed a patient base, begun a series of clinical trials, and created an ongoing forum for communicating new research initiatives and findings. In addition, Dr. .Von Hoff, the principal investigator for this application, has stepped down from the Directorship of the Arizona Cancer Center to devote full time to this effort. Our approach to make a difference against pancreatic cancer focuses on the development of innovative, translational ways to tackle the disease. Out of that groundwork effort comes this P01 application focusing on pancreatic cancer. As we hope the reviewers will see, our team has already made substantial progress in identifying new targets in and indeed new approaches to pancreatic cancer. This P01 application focuses that ongoing work and translates that work into new therapeutics that will be brought into patients. This P01 contains three translational research projects whose collective aims are to develop new therapeutics for patients with pancreatic cancer. These related Projects include: (1) Treatment of Hypoxia Resistance in Pancreatic Cancer; (2) Method to Eliminate Pancreatic Cells with Specific Patterns of Mutations/Deletions; and (3) Validation of Amplified Genes in Pancreatic Cancer: New sensitizing Targets for Improved Gemcitabine Therapy. Each project already has some leads and each project is designed to maximize translational potential. As will be seen in the application, the Projects are highly integrated so there is the highest probability we can bring that one therapeutic to the clinic each year. The projects are supported by four highly-integrated shared services (cores): (1) Pancreatic Cancer Biospecimens Repository; (2) Pattern Analysis and Computational Biology Core; (3) Drug Development Core; and (4) Evaluation and Administration Core. These cores provide material, informatic, development and administrative support for the projects. Since we are blessed by having such excellent shared services at the Arizona Cancer Center (AZCC), the cores in this proposed P01 are designed to utilize those cores and therefore for this application we are only asking for resources to provide the services that are over an above the services that can be provided by these AZCC cores. In addition, both internal and external scientific advisory boards are included in the P01 to assure maximum input into the science and into the execution of the Projects. The overall goal of this P01 is the delivery into the clinic one new therapeutic agent against a new target in pancreatic cancer each year of the P01. We feel this effort, with new approaches to pancreatic cancer, concentrated in a P01, has a chance to make an impact on the disease.

描述（由申请人提供）：胰腺癌现在是美国女性和男性癌症死亡的第四大原因。迫切需要新的创新方法来预防和治疗胰腺癌。这个计划项目补助金（P01）在胰腺癌的应用需要具有挑战性的需求，建立在一个强大的基础上的兴趣和专业知识在胰腺癌和药物开发在亚利桑那州癌症中心（AZCC）在亚利桑那大学。本P01的中心主题和目标是加速针对胰腺癌新靶点的新治疗药物的临床应用。这个P01的目标是，在这个P01的每一年，我们将在胰腺癌患者的临床试验中提供一种新的药物，它击中了在这个P01的一个项目中发现和验证的目标。 这个P01应用程序代表了一个修订的应用程序，我们认为这是一个改进的，更集中的努力对付这种疾病。对每个批评的回应都在应用程序的每个部分的开头。 两年前，AZCC成立了悉尼鲑鱼胰腺癌小组（以AZCC的创始董事命名，他死于这种疾病）。该团队已经建立了一个基础设施的研究人员（已建立和新的，在基础，转化和临床研究），开发了一个患者基础，开始了一系列的临床试验，并创建了一个持续的论坛，用于交流新的研究计划和发现。此外，本申请的主要研究员冯霍夫博士已辞去亚利桑那州癌症中心主任的职务，将全部时间投入到这项工作中。我们对胰腺癌有所作为的方法侧重于开发创新的转化方法来应对这种疾病。在这一基础工作的基础上，这个P01应用程序专注于胰腺癌。正如我们希望评论者看到的那样，我们的团队已经在确定胰腺癌的新靶点和新方法方面取得了实质性进展。这个P01应用程序专注于正在进行的工作，并将该工作转化为将被带到患者体内的新疗法。 P01包含三个转化研究项目，其共同目标是为胰腺癌患者开发新的治疗方法。这些相关项目包括：（1）胰腺癌中缺氧抗性的治疗;（2）消除具有特定突变/缺失模式的胰腺细胞的方法;和（3）胰腺癌中扩增基因的验证：用于改进吉西他滨治疗的新增敏靶点。每个项目都已经有一些线索，每个项目都旨在最大限度地发挥翻译潜力。正如在申请中所看到的那样，这些项目是高度集成的，因此我们每年将一种治疗药物带到诊所的可能性最高。 这些项目由四个高度集成的共享服务（核心）支持：（1）胰腺癌生物标本库;（2）模式分析和计算生物学核心;（3）药物开发核心;以及（4）评估和管理核心。这些核心为项目提供物质、信息、发展和行政支助。 由于我们有幸在亚利桑那州癌症中心（AZCC）拥有如此出色的共享服务，因此本提议的P01中的核心旨在利用这些核心，因此对于此应用程序，我们仅要求资源提供超过这些AZCC核心可以提供的服务的服务。此外，内部和外部科学咨询委员会都包括在P01中，以确保对科学和项目执行的最大投入。 P01的总体目标是每年向临床提供一种针对胰腺癌新靶点的新治疗药物。我们认为这项努力，与胰腺癌的新方法，集中在P01，有机会对疾病产生影响。

项目成果

MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer.

• DOI: 10.1002/ijc.25924
• 发表时间: 2011-12-01
• 期刊: INTERNATIONAL JOURNAL OF CANCER
• 影响因子: 6.4
• 作者: Kuuselo, Riina;Savinainen, Kimmo;Sandstrom, Saana;Autio, Reija;Kallioniemi, Anne
• 通讯作者: Kallioniemi, Anne

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

• DOI: 10.1158/1078-0432.ccr-10-2214
• 发表时间: 2011-05-01
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
• 作者: Diep CH;Munoz RM;Choudhary A;Von Hoff DD;Han H
• 通讯作者: Han H

High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.

• DOI: 10.1158/1541-7786.mcr-10-0436
• 发表时间: 2011-06
• 期刊: Molecular cancer research : MCR
• 作者: Henderson MC;Gonzales IM;Arora S;Choudhary A;Trent JM;Von Hoff DD;Mousses S;Azorsa DO
• 通讯作者: Azorsa DO

Context-specific gene regulatory networks subdivide intrinsic subtypes of breast cancer.

• DOI: 10.1186/1471-2105-12-s2-s3
• 发表时间: 2011-03-29
• 期刊: BMC bioinformatics
• 影响因子: 3
• 作者: Nasser S;Cunliffe HE;Black MA;Kim S
• 通讯作者: Kim S

UA62784, a novel inhibitor of centromere protein E kinesin-like protein.

• DOI: 10.1158/1535-7163.mct-08-0789
• 发表时间: 2009-01
• 期刊: Molecular cancer therapeutics
• 影响因子: 5.7
• 作者: Henderson MC;Shaw YJ;Wang H;Han H;Hurley LH;Flynn G;Dorr RT;Von Hoff DD
• 通讯作者: Von Hoff DD